home / stock / rarx / rarx quote
Last: | $47.99 |
---|---|
Change Percent: | -0.04% |
Open: | $47.99 |
Close: | $47.99 |
High: | $48.01 |
Low: | $47.98 |
Volume: | 4,068,616 |
Last Trade Date Time: | 04/01/2020 04:47:15 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$47.99 | $47.99 | $47.99 | $48.01 | $47.98 | 4,068,616 | 04-01-2020 |
$48.01 | $47.96 | $48.01 | $48.02 | $47.96 | 7,172,769 | 03-31-2020 |
$47.34 | $47.11 | $47.34 | $47.5 | $46.91 | 1,197,539 | 03-30-2020 |
$46.9 | $47.01 | $46.9 | $47.355 | $46.78 | 1,208,561 | 03-27-2020 |
$46.96 | $47.65 | $46.96 | $47.74 | $46.34 | 1,618,487 | 03-26-2020 |
$47.56 | $46 | $47.56 | $47.77 | $44.5 | 5,564,677 | 03-25-2020 |
$45.95 | $45.96 | $45.95 | $46.2 | $43.78 | 1,039,102 | 03-24-2020 |
$45.36 | $45.63 | $45.36 | $45.99 | $44.63 | 900,749 | 03-23-2020 |
$45.7 | $45.69 | $45.7 | $46.2 | $44.31 | 1,074,077 | 03-20-2020 |
$45.21 | $40.49 | $45.21 | $45.74 | $40.49 | 1,735,750 | 03-19-2020 |
$ | $46.19 | $46.23 | $46.23 | $46.01 | 731,972 | 02-12-2020 |
$ | $46.35 | $46.18 | $46.37 | $46.12 | 797,921 | 02-11-2020 |
$ | $46.37 | $46.26 | $46.37 | $46.19 | 387,067 | 02-10-2020 |
$ | $46.45 | $46.30 | $46.50 | $46.30 | 429,243 | 02-07-2020 |
$ | $46.60 | $46.43 | $46.60 | $46.38 | 531,278 | 02-06-2020 |
$ | $46.68 | $46.54 | $46.68 | $46.46 | 1,198,432 | 02-05-2020 |
$ | $46.80 | $46.60 | $46.83 | $46.545 | 750,798 | 02-04-2020 |
$ | $46.91 | $46.80 | $46.98 | $46.71 | 1,030,255 | 02-03-2020 |
$ | $46.98 | $46.87 | $47.015 | $46.84 | 1,033,299 | 01-31-2020 |
$ | $47.05 | $46.97 | $47.07 | $46.96 | 885,006 | 01-30-2020 |
News, Short Squeeze, Breakout and More Instantly...
Ra Pharmaceuticals Inc. Company Name:
RARX Stock Symbol:
NASDAQ Market:
Ra Pharmaceuticals Inc. Website:
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) is joining forces with 30 million healthcare advocates around the world for the 13 th Annual Rare Disease Day ® , an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people l...
Enrollment ongoing in Phase 3 clinical trial of zilucoplan in gMG, with top-line results expected in early 2021 First patient dosed in Phase 2 clinical trial of zilucoplan in IMNM, with top-line results expected in the second half of 2020 IND cleared by FDA for the HEALEY ALS Plat...
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Direc...